MCID: MCL030
MIFTS: 25

Macular Degeneration, Age-Related, 10

Categories: Eye diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Macular Degeneration, Age-Related, 10

MalaCards integrated aliases for Macular Degeneration, Age-Related, 10:

Name: Macular Degeneration, Age-Related, 10 54 71 13 69
Armd10 12 71
Age Related Macular Degeneration 10 12
Age-Related Macular Degeneration 10 29

Classifications:



External Ids:

OMIM 54 611488
Disease Ontology 12 DOID:0110022
MedGen 40 C1969108
MeSH 42 D008268

Summaries for Macular Degeneration, Age-Related, 10

UniProtKB/Swiss-Prot : 71 Macular degeneration, age-related, 10: A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.

MalaCards based summary : Macular Degeneration, Age-Related, 10, also known as armd10, is related to eye disease. An important gene associated with Macular Degeneration, Age-Related, 10 is ARMD10 (Macular Degeneration, Age-Related, 10). The drugs Ranibizumab and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina.

Disease Ontology : 12 An age related macular degeneration associated with variation in the genomic region 9:112,100,000-127,500,000 (GRCh38). TLR4 has been put forth as a candidate gene.

Description from OMIM: 611488

Related Diseases for Macular Degeneration, Age-Related, 10

Symptoms & Phenotypes for Macular Degeneration, Age-Related, 10

Clinical features from OMIM:

611488

Drugs & Therapeutics for Macular Degeneration, Age-Related, 10

Drugs for Macular Degeneration, Age-Related, 10 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 166)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
2
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
3
Verteporfin Approved, Investigational Phase 4,Phase 3,Phase 2 129497-78-5
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-02-2 5743
5
Nepafenac Approved Phase 4,Phase 2 78281-72-8 151075
6
Zinc Approved Phase 4 7440-66-6 32051 23994
7
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 124-94-7 31307
8
Eplerenone Approved Phase 4 107724-20-9 150310 443872
9
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
10 Tocopherol Approved, Nutraceutical Phase 4,Phase 3
11
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
12
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-02-9 14985
13 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
14 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
15 Endothelial Growth Factors Phase 4,Phase 2,Phase 3,Phase 1
16 Mitogens Phase 4,Phase 2,Phase 3,Phase 1
17 Anti-Bacterial Agents Phase 4,Phase 1,Phase 2
18 Anti-Infective Agents Phase 4,Phase 1,Phase 2
19 Tocopherols Phase 4,Phase 3
20 Tocotrienols Phase 4,Phase 3
21 Vitamins Phase 4,Phase 3,Phase 1
22 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
23 Dermatologic Agents Phase 4,Phase 3,Phase 2
24 Photosensitizing Agents Phase 4,Phase 3,Phase 2
25 Antiemetics Phase 4,Phase 3,Phase 1,Phase 2
26 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2
28 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2
29 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2
30 Dexamethasone acetate Phase 4,Phase 3,Phase 1,Phase 2 1177-87-3
31 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
32 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
33 HIV Protease Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
34 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
35 Hormones Phase 4,Phase 3,Phase 2,Phase 1
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
37 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
38
protease inhibitors Phase 4,Phase 3,Phase 1,Phase 2
39 Analgesics Phase 4,Phase 2
40 Analgesics, Non-Narcotic Phase 4,Phase 2
41 Antibiotics, Antitubercular Phase 4
42 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
43 Antirheumatic Agents Phase 4,Phase 2
44 Antibodies Phase 4,Phase 3,Phase 2
45 Antibodies, Monoclonal Phase 4,Phase 2
46 Immunoglobulins Phase 4,Phase 3,Phase 2
47 diuretics Phase 4,Phase 2
48 Diuretics, Potassium Sparing Phase 4
49 Natriuretic Agents Phase 4,Phase 2
50 Immunosuppressive Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 177)

id Name Status NCT ID Phase Drugs
1 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
2 Safety and Tolerability of Ranibizumab in Mono/Bilateral w-AMD Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye Completed NCT01986907 Phase 4 ranibizumab
3 FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration Completed NCT01500915 Phase 4 Ranibizumab
4 Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial Completed NCT00751361 Phase 4
5 Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing Completed NCT01453920 Phase 4 Ranibizumab;Ranibizumab
6 Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Primarily Intra-retinal Fluid) Treatment. Completed NCT01972789 Phase 4 Ranibizumab
7 Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4 aflibercept
8 Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy Completed NCT01797861 Phase 4
9 Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) Completed NCT01775124 Phase 4 Ranibizumab
10 Visual Outcome in Patients With Symptomatic Macular PCV Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy. Completed NCT01846273 Phase 4 Ranibizumab;Verteporfin PDT;Sham PDT
11 Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD Completed NCT01958918 Phase 4 Ranibizumab;Aflibercept
12 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed NCT02036424 Phase 4 Ozurdex;Bevacizumab
13 A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema Completed NCT01315275 Phase 4 Ranibizumab
14 CME With Different Fluidic Parameters Completed NCT01385852 Phase 4
15 Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery Completed NCT00494494 Phase 4 Standard Care;nepafenac
16 Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration Recruiting NCT02944227 Phase 4 Lucentis
17 Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD Recruiting NCT02810808 Phase 4 Ranibizumab
18 Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye Recruiting NCT02581891 Phase 4 Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321);Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
19 Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy Recruiting NCT03079141 Phase 4 Eplerenone
20 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Recruiting NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
21 Treatment of AMD With Rheohemapheresis /RHF/ Active, not recruiting NCT01943396 Phase 4
22 VITAL - Individualising Therapy for Neovascular AMD With Aflibercept Active, not recruiting NCT02441816 Phase 4 Aflibercept
23 Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision Active, not recruiting NCT01795209 Phase 4 Ranibizumab
24 Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy Not yet recruiting NCT02976194 Phase 4 ranibizumab
25 TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection Terminated NCT01983579 Phase 4
26 Investigation of Macular Pigment Augmentation on Dark Adaptation Terminated NCT00478439 Phase 4
27 Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy Withdrawn NCT01666236 Phase 4
28 TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration Unknown status NCT00260403 Phase 2, Phase 3
29 Subretinal Macugen® for Neovascular Age-Related Macular Degeneration Unknown status NCT00788177 Phase 3 Pegaptanib (Macugen®)
30 Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients Unknown status NCT02296567 Phase 2, Phase 3 Ranibizumab;Bevacizumab;Aflibercept;Ranibizumab;Bevacizumab;Aflibercept;Ranibizumab;Bevacizumab;Aflibercept
31 A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib Completed NCT00242580 Phase 3 Verteporfin photodynamic therapy;Pegaptanib;Triamcinolone acetonide
32 Improving Function in Age-Related Macular Degeneration Completed NCT00572039 Phase 3
33 Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial Completed NCT00593450 Phase 3 ranibizumab;bevacizumab
34 Age-Related Eye Disease Study 2 (AREDS2) Completed NCT00345176 Phase 3 Lutein/zeaxanthin and DHA/EPA
35 Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration Completed NCT00100009 Phase 3 TAC-PF;Triamcinolone Acetonide
36 French Evaluation Group Avastin Versus Lucentis Completed NCT01170767 Phase 3 Avastin;Lucentis
37 Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration Completed NCT01780935 Phase 3 Ranibizumab
38 Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride Completed NCT01802866 Phase 2, Phase 3 ACU-4429;Placebo
39 Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Completed NCT00436553 Phase 3 Verteporfin Photodynamic Therapy;Ranibizumab;Verteporfin Placebo;Ranibizumab Placebo
40 Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD Completed NCT01948830 Phase 3 Ranibizumab 0.5mg;Ranibizumab 0.5mg
41 A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration Completed NCT00061594 Phase 3 rhuFab V2 (ranibizumab)
42 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) Completed NCT00637377 Phase 3 Ranibizumab
43 A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema Completed NCT01100307 Phase 3 pegaptanib sodium
44 A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema Completed NCT00148265 Phase 2, Phase 3 Triamcinolone acetate
45 A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension. Completed NCT00605280 Phase 2, Phase 3 Standard of Care;Macugen
46 Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy Completed NCT00445003 Phase 3 Ranibizumab;Triamcinolone Acetonide
47 Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) Recruiting NCT02745119 Phase 3 Lampalizumab
48 Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD) Recruiting NCT02540954 Phase 3 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
49 A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Patients With Diabetic Macular Edema Recruiting NCT02121262 Phase 3 700 μg dexamethasone
50 Treatment for CI-DME in Eyes With Very Good VA Study Recruiting NCT01909791 Phase 3 Prompt aflibercept;Deferred aflibercept

Search NIH Clinical Center for Macular Degeneration, Age-Related, 10

Genetic Tests for Macular Degeneration, Age-Related, 10

Genetic tests related to Macular Degeneration, Age-Related, 10:

id Genetic test Affiliating Genes
1 Age-Related Macular Degeneration 10 29

Anatomical Context for Macular Degeneration, Age-Related, 10

MalaCards organs/tissues related to Macular Degeneration, Age-Related, 10:

39
Eye, Endothelial, Retina

Publications for Macular Degeneration, Age-Related, 10

Variations for Macular Degeneration, Age-Related, 10

Expression for Macular Degeneration, Age-Related, 10

Search GEO for disease gene expression data for Macular Degeneration, Age-Related, 10.

Pathways for Macular Degeneration, Age-Related, 10

GO Terms for Macular Degeneration, Age-Related, 10

Sources for Macular Degeneration, Age-Related, 10

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....